Abstract:The pathogenesis of atopic dermatitis (AD) is understood to be crucially influenced by three main factors: dysregulation of the immune response, barrier dysfunction, and pruritus. In the lesional skin of AD, various innate immune cells, including Th2 cells, type 2 innate lymphoid cells (ILC2s), and basophils, produce Th2 cytokines [interleukin (IL)-4, IL-5, IL-13, IL-31]. Alarmins such as TSLP, IL-25, and IL-33 are also produced by epidermal keratinocytes, amplifying type 2 inflammation. In the chronic phase, not only Th2 cells but also Th22 and Th17 cells increase in number, leading to suppression of filaggrin expression by IL-4, IL-13, and IL-22, which further deteriorates the epidermal barrier function. Dupilumab, which targets IL-4 and IL-13, has shown efficacy in treating moderate to severe AD. Nemolizumab, targeting IL-31RA, effectively reduces pruritus in AD patients. In addition, clinical trials with fezakinumab, targeting IL-22, have demonstrated promising results, particularly in severe AD cases. Conversely, in murine models of AD, several cytokines, initially regarded as promising therapeutic targets, have not demonstrated sufficient efficacy in clinical trials. IL-33 has been identified as a potent activator of immune cells, exacerbating AD in murine models and correlating with disease severity in human patients. However, treatments targeting IL-33 have not shown sufficient efficacy in clinical trials. Similarly, thymic stromal lymphopoietin (TSLP), integral to type 2 immune responses, induces dermatitis in animal models and is elevated in human AD, yet clinical treatments like tezepelumab exhibit limited efficacy. Therapies targeting IL-1α, IL-5, and IL-17 also failed to achieve sufficient efficacy in clinical trials. It has become clear that for treating AD, IL-4, IL-13, and IL-31 are relevant therapeutic targets during the acute phase, while IL-22 emerges as a target in more severe cases. This delineation underscores the necessity of considering distinct pathophysiological aspects and therapeutic targets in AD between mouse models and humans. Consequently, this review delineates the distinct roles of cytokines in the pathogenesis of AD, juxtaposing their significance in human AD from clinical trials against insights gleaned from AD mouse models. This approach will improve our understanding of interspecies variation and facilitate a deeper insight into the pathogenesis of AD in humans.

Cd1d Restricted Natural Killer T Cells Are Not Required for Allergic Skin Inflammation

Exaggerated IL-17 Response to Epicutaneous Sensitization Mediates Airway Inflammation in the Absence of IL-4 and IL-13.

Allergic inflammation is augmented via histamine H4 receptor activation: The role of natural killer cells in vitro and in vivo

Altered natural killer cell responses linked to allergen sensitization in patients with atopic dermatitis

IFN-γ–dependent Interactions Between Tissue-Intrinsic Γδ T Cells and Tissue-Infiltrating CD8 T Cells Limit Allergic Contact Dermatitis

Natural killer T cells are essential for the development of contact hypersensitivity in BALB/c mice

Epicutaneous Antigen Challenge of Orally Sensitized Mice Elicits Allergic Dermatitis by Redirecting Α4β7 Gut Homing T Cells to the Skin (79.7)

Ezh2 controls development of natural killer T cells, which cause spontaneous asthma-like pathology

Allergic Inflammation is Exacerbated by Allergen-Induced Type 2 Innate Lymphoid Cells in a Murine Model of Allergic Rhinitis.

CD137 deficiency does not affect development of airway inflammation or respiratory tolerance induction in murine models

MR1 deficiency enhances IL-17-mediated allergic contact dermatitis

Interplay of cytokines in the pathophysiology of atopic dermatitis: insights from Murin models and human

CD4+ T Cells Induce Productions of IL-5 and IL-13 Through MHCII on ILC2s in a Murine Model of Allergic Rhinitis.

The expression of CD+4 invariant T cell receptor and natural killer T cells in the experimental allergic rhinitis

Invariant Natural Killer T Cells Regulate Conventional Dendritic Cell Maturation to Re-establish Immune Tolerance to Rheumatoid Arthritis in DBA/1 Mice

Autologous Th2-polarized lymphocytes induce atopic dermatitis lesions in non-atopic human skin xenotransplants

The interaction between NK cells and ILC cells and their subsets in atopic dermatitis patients with and without dupilumab therapy

iNKT Cells Suppress Pathogenic NK1.1+CD8+ T Cells in DSS-Induced Colitis

Progressive accumulation of hyperinflammatory NKG2D low NK cells in early childhood severe atopic dermatitis

Genomic control of inflammation in experimental atopic dermatitis

Gene expression analysis of atopic dermatitis-like skin lesions induced in NC/Nga mice by mite antigen stimulation under specific pathogen-free conditions